TGFb inhibitors - Pipeline Insight, 2024

This “TGF-Beta Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in TGF-Beta Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

TGF-Beta Inhibitors Understanding

TGF-Beta Inhibitors: Overview

Transforming growth factor (TGF)-ß is a secreted multifunctional cytokine that signals via plasma membrane TGF-ß type I and type II receptors and intercellular SMAD transcriptional effectors. Aberrant inter- and intracellular TGF-ß signaling can contribute to cancer progression. In normal cells and early stages of cancer, TGF-ß can stimulate epithelial growth arrest and elicit a tumor suppressor function. However, in late stages of cancer, when the cytostatic effects of TGF-ß in cancer cells are blocked, TGF-ß signaling can act as tumor promoter by its ability to stimulate epithelial-to-mesenchymal transition of cancer cells, by stimulating angiogenesis, and by promoting evasion of immune responses.

Transforming growth factor ß (TGF-ß) is part of a larger superfamily of secreted dimeric multifunctional proteins that also includes activins and bone morphogenetic proteins. It plays an important role in embryogenesis and in maintaining tissue homeostasis in multicellular organisms. TGF-ß elicits highly context-dependent effects on many different cell types. Hence, anomalous TGF-ß signaling can result in numerous diseases, including cancer. TGF-ß signaling can have a dual role in cancer

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence TGF-Beta Inhibitors R&D. The therapies under development are focused on novel approaches for TGF-Beta Inhibitors.
• In July 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio.

TGF-Beta Inhibitors Emerging Drugs Chapters

This segment of the TGF-Beta Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TGF-Beta Inhibitors Emerging Drugs

• Luspatercept - Acceleron Pharma

Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling.

TGF-Beta Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different TGF-Beta Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on TGF-Beta Inhibitors

There are approx. 10+ key companies which are developing the TGF-Beta Inhibitors. The companies which have their TGF-Beta Inhibitors drug candidates in the most advanced stage, i.e. phase III include, Luspatercept.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

TGF-Beta Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TGF-Beta Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TGF-Beta Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TGF-Beta Inhibitors drugs.

TGF-Beta Inhibitors Report Insights

• TGF-Beta Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

TGF-Beta Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing TGF-Beta Inhibitors drugs?
• How many TGF-Beta Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for TGF-Beta Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TGF-Beta Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for TGF-Beta Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Acceleron Pharma
• Isarna Therapeutics
• Forbius

Key Products

• Luspatercept
• ISTH0036
• ISTH1106
• ISTH0047
• ISTH1047
• AVID 200